LEE011 (Ribociclib) is an orally bioavailable, highly selective, ATP-competitive CDK4/6 inhibitor. It affects the CDK4/6-Rb signaling pathway. By binding to the ATP-binding pocket and blocking Rb phosphorylation, it induces G1 phase cell cycle arrest and effectively inhibits cancer cell proliferation.
LEE011 (Ribociclib) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for LEE011 (Ribociclib) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.